The acquisition aims to expand Kite Pharma’s capabilities in in vivo CAR T-cell therapy research and development.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

所以对于各IN VIVO CAR-T平台/公司的评估，评估其载体特点及后续的转染、表达、安全性等参数是重中之重。目前主流的载体分为病毒载体和非病毒载体，后续我将根据载体及代表公司，做个系列的文章来梳理。今天重点来讨论一下病毒载体，特别是慢病毒载体。

Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.

Gilead subsidiary Kite Pharma said that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million.

Interius Bio基因治疗服务商，专注于血液系统恶性肿瘤，为用户提供癌症基因治疗及细胞免疫解决方案。近日，Kite以3.5亿美元收购Interius Bio。

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Gilead will integrate Interius, the first biotech to push an in vivo CAR-T therapy into the clinic, into its cell therapy ...

8月21日，吉利德科学宣布以3.5亿美元全资收购CAR-T疗法开发公司Interius ...

当下，随着吉利德的入局，体内CAR-T领域的“多国杀”格局初定，巨头的军备竞赛已进入白热化。这场竞赛的背后，不仅是对下一代技术制高点的争夺，更是对细胞治疗未来形态的定义权之争。

【吉利德3.5亿美元收购Interius 布局体内细胞疗法】《科创板日报》22日讯，吉利德公司旗下的Kite宣布已达成最终协议，以3.5亿美元收购生物技术公司Interius BioTherapeutics，以布局体内 (in ...

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.